CO2 Chromatography Separates Ondansetron Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for separating ondansetron and its highly polar related impurities, such as 2-methylimidazole and imidazole, are challenging due to close retention time differences, making strict compliance with regulatory limits difficult, especially in high-throughput quality control analyses.
Innovation Solution
CO2-based chromatography methods that provide orthogonal selectivity, reducing solvent consumption and analysis time, and do not require pre-column derivatization or ion-pairing reagents, allowing for effective separation of ondansetron and its impurities using commercially available columns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If reverse phase HPLC is used to separate ondansetron and its impurities, then separation can be performed, but the retention time difference between impurities is too small (0.02-0.05 seconds) to achieve adequate separation
Solution Approach 1:
The patent changes the fundamental separation parameter from reverse phase HPLC to CO2-based chromatography (supercritical fluid chromatography). This parameter change transforms the separation mechanism, allowing highly polar impurities to be retained with sufficient resolution while maintaining analysis time efficiency.
Solution Approach 2:
The patent replaces the traditional HPLC mechanical separation system with a CO2-based chromatography system. This substitution enables better separation of highly polar compounds by utilizing the unique properties of supercritical CO2 as a mobile phase, achieving both adequate retention time differences and high throughput.
2Manufacturing precision
If traditional HPLC methods are used, then separation is possible, but solvent consumption is high and analysis time is long
Solution Approach 1:
The patent changes the mobile phase parameter from traditional HPLC solvents to CO2-based chromatography. This parameter change reduces solvent consumption significantly while shortening analysis time, thereby improving productivity without sacrificing separation quality for quality control applications.
Solution Approach 2:
The patent utilizes CO2, which can be easily vented and replaced, as the mobile phase. This approach reduces the need for large volumes of expensive organic solvents and allows for faster method transitions, enhancing high throughput capability.
3Manufacturing precision
If ion-pairing or elaborate column materials are used to separate highly polar impurities, then separation resolution improves, but device complexity and method complexity increase
Solution Approach 1:
The patent extracts the highly polar impurities from the complex mixture and separates them using CO2-based chromatography. This approach eliminates the need for ion-pairing reagents and elaborate column materials, simplifying the device and method while achieving the required separation resolution.
4Manufacturing precision
If high buffer concentrations and long equilibration times are used, then separation of polar impurities improves, but analysis time and productivity decrease
Solution Approach 1:
The patent changes the chromatography parameter from high buffer concentration HPLC to CO2-based chromatography. This parameter change enables effective separation of polar impurities without requiring high buffer concentrations or long equilibration times, thus maintaining high productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable reliable, high-throughput separation of ondansetron and its impurities with extended retention times and reduced solvent use, ensuring compliance with regulatory standards while optimizing separation efficiency.
Implementation Method 1
separating ondansetron and related impurities using CO2-based chromatography
Data Source
AI summary
The present disclosure generally relates to methods for separating ondansetron and related impurities using CO2-based chromatography.